日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

Optimizing assessment of CD30 expression in Hodgkin lymphoma by controlling for low expression

通过控制低表达来优化霍奇金淋巴瘤中 CD30 表达的评估

Sarwar, Shoib; Tome, Margaret E; Billheimer, Dean; Spier, Catherine; Smith, Catharine L; Persky, Daniel; Schmelz, Monika

Subclonal TP53 mutations are frequent and predict resistance to radioimmunotherapy in follicular lymphoma

亚克隆TP53突变常见,并可预测滤泡性淋巴瘤对放射免疫疗法的耐药性。

Burack, W Richard; Li, Hongli; Adlowitz, Diana; Spence, Janice M; Rimsza, Lisa M; Shadman, Mazyar; Spier, Catherine M; Kaminski, Mark S; Leonard, John P; Leblanc, Michael L; Smith, Sonali M; Friedberg, Jonathan W

Peripheral T-Cell Lymphoma in a Patient Previously Diagnosed With Sarcoidosis

既往诊断为结节病患者出现外周T细胞淋巴瘤

Menghani, Sanjay V; Diaz-Hanson, Jessica P; Heimbigner, Alex; Wakefield, Chelby; Fuchs, Deborah; Reveles, Candace Y; Spier, Catherine; Amaraneni, Akshay; Kumar, Abhijeet

SARS-CoV-2 Rapid Antigen Testing of Symptomatic and Asymptomatic Individuals on the University of Arizona Campus

亚利桑那大学校园内有症状和无症状个体的SARS-CoV-2快速抗原检测

Harris, David T; Badowski, Michael; Jernigan, Brandon; Sprissler, Ryan; Edwards, Taylor; Cohen, Randall; Paul, Stephen; Merchant, Nirav; Weinkauf, Craig C; Bime, Christian; Erickson, Heidi E; Bixby, Billie; Parthasarathy, Sairam; Chaudhary, Sachin; Natt, Bhupinder; Cristan, Elaine; El Aini, Tammer; Rischard, Franz; Campion, Janet; Chopra, Madhav; Insel, Michael; Sam, Afshin; Knepler, James L; Knox, Kenneth; Mosier, Jarrod; Spier, Catherine; Dake, Michael D

Continued Excellent Outcomes in Previously Untreated Patients With Follicular Lymphoma After Treatment With CHOP Plus Rituximab or CHOP Plus (131)I-Tositumomab: Long-Term Follow-Up of Phase III Randomized Study SWOG-S0016

在接受 CHOP 联合利妥昔单抗或 CHOP 联合 (131)I-托西莫单抗治疗的既往未接受治疗的滤泡性淋巴瘤患者中,疗效持续良好:III 期随机研究 SWOG-S0016 的长期随访

Shadman, Mazyar; Li, Hongli; Rimsza, Lisa; Leonard, John P; Kaminski, Mark S; Braziel, Rita M; Spier, Catherine M; Gopal, Ajay K; Maloney, David G; Cheson, Bruce D; Dakhil, Shaker; LeBlanc, Michael; Smith, Sonali M; Fisher, Richard I; Friedberg, Jonathan W; Press, Oliver W

Phase I Study of the Investigational Aurora A Kinase Inhibitor Alisertib plus Rituximab or Rituximab/Vincristine in Relapsed/Refractory Aggressive B-cell Lymphoma

在复发/难治性侵袭性B细胞淋巴瘤中,研究性Aurora A激酶抑制剂Alisertib联合利妥昔单抗或利妥昔单抗/长春新碱的I期研究

Kelly, Kevin R; Friedberg, Jonathan W; Park, Steven I; McDonagh, Kevin; Hayslip, John; Persky, Daniel; Ruan, Jia; Puvvada, Soham; Rosen, Peter; Iyer, Swaminathan Padmanabhan; Stefanovic, Alexandra; Bernstein, Steven H; Weitman, Steven; Karnad, Anand; Monohan, Gregory; VanderWalde, Ari; Mena, Raul; Schmelz, Monika; Spier, Catherine; Groshen, Susan; Venkatakrishnan, Karthik; Zhou, Xiaofei; Sheldon-Waniga, Emily; Leonard, E Jane; Mahadevan, Daruka

Impact of histological grading on survival in the SWOG S0016 follicular lymphoma cohort

组织学分级对SWOG S0016滤泡性淋巴瘤队列生存率的影响

Rimsza, Lisa M; Li, Hongli; Braziel, Rita M; Spier, Catherine M; Persky, Daniel O; Dunlap, Jennifer; LeBlanc, Michael; Bartlett, Nancy; Leonard, John P; Smith, Sonali M; Press, Oliver W; Friedberg, Jonathan W

Phase II Intergroup Trial of Alisertib in Relapsed and Refractory Peripheral T-Cell Lymphoma and Transformed Mycosis Fungoides: SWOG 1108

Alisertib治疗复发/难治性外周T细胞淋巴瘤和转化型蕈样肉芽肿的II期多中心试验:SWOG 1108

Barr, Paul M; Li, Hongli; Spier, Catherine; Mahadevan, Daruka; LeBlanc, Michael; Ul Haq, Mansoor; Huber, Bryan D; Flowers, Christopher R; Wagner-Johnston, Nina D; Horwitz, Steven M; Fisher, Richard I; Cheson, Bruce D; Smith, Sonali M; Kahl, Brad S; Bartlett, Nancy L; Friedberg, Jonathan W

Genetic polymorphisms in oxidative stress-related genes are associated with outcomes following treatment for aggressive B-cell non-Hodgkin lymphoma

氧化应激相关基因的遗传多态性与侵袭性B细胞非霍奇金淋巴瘤治疗后的预后相关

Gustafson, Heather L; Yao, Song; Goldman, Bryan H; Lee, Kristy; Spier, Catherine M; LeBlanc, Michael L; Rimsza, Lisa M; Cerhan, James R; Habermann, Thomas M; Link, Brian K; Maurer, Matthew J; Slager, Susan L; Persky, Daniel O; Miller, Thomas P; Fisher, Richard I; Ambrosone, Christine B; Briehl, Margaret M

Phase III randomized intergroup trial of CHOP plus rituximab compared with CHOP chemotherapy plus (131)iodine-tositumomab for previously untreated follicular non-Hodgkin lymphoma: SWOG S0016

一项针对既往未接受治疗的滤泡性非霍奇金淋巴瘤患者的 III 期随机多中心试验,比较了 CHOP 联合利妥昔单抗与 CHOP 化疗联合 (131)碘-托西莫单抗的疗效:SWOG S0016

Press, Oliver W; Unger, Joseph M; Rimsza, Lisa M; Friedberg, Jonathan W; LeBlanc, Michael; Czuczman, Myron S; Kaminski, Mark; Braziel, Rita M; Spier, Catherine; Gopal, Ajay K; Maloney, David G; Cheson, Bruce D; Dakhil, Shaker R; Miller, Thomas P; Fisher, Richard I